Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

South Korean court suspends regulator's disciplinary action against Samsung BioLogics

Published 01/22/2019, 01:40 AM
Updated 01/22/2019, 01:40 AM
© Reuters.  South Korean court suspends regulator's disciplinary action against Samsung BioLogics

By Ju-min Park and Heekyong Yang

SEOUL (Reuters) - A South Korean court has suspended the financial regulator's disciplinary action against Samsung (KS:005930) BioLogics Co Ltd (KS:207940) for allegedly breaching accounting rules, an official at the Seoul Administrative Court said on Tuesday.

In November, the Financial Services Commission (FSC) said the biotech arm of Samsung Group intentionally breached accounting rules ahead of its 2016 listing. It called for the firm's chief executive officer and chief finance officer to be fired, imposed fines, and requested the firm correct its balance sheet.

Samsung BioLogics filed an administrative lawsuit at the Seoul Administrative Court to nullify the watchdog's findings and sought an injunction to halt any disciplinary action until the court rules on the matter.

"The court concluded that an immediate sanction on the company could lead to irreparable damage when its violation of accounting standards has yet to be proven in court," the court official said, declining to be identified due to the sensitivity of the matter.

The FSC in a statement said it will review details of the court's ruling and plan whether to immediately file an appeal.

Samsung BioLogics, which has denied wrongdoing, confirmed the court's decision to suspend any sanctions.

"The court's decision is fortunate. We will do our best to prove the legitimacy of the company's handling of accounting," a Samsung official said by telephone.

Samsung must now await the outcome of the prosecutors' investigation, the timing of which is unknown.

Samsung BioLogics' head office was raided by South Korean prosecutors last month as part of a criminal probe into alleged accounting fraud after the financial regulator filed a complaint.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Shares of Samsung BioLogics were suspended following the regulator's findings, and resumed trading in December after the bourse decided the company was qualified to remain listed.

The stock was up 0.1 percent on Tuesday, compared with a 0.7 percent decline in the Kospi benchmark share price index (KS11).

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.